1. Pink Sheet
  2. >>Market Access

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

 
• By Cathy Kelly

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

Cost Sharing In Commercial Market Will Be Capped For Lilly's Insulin • Source: Shutterstock

In a move described as filling the gap left when the Inflation Reduction Act passed with a $35 cap on patient cost sharing for insulin in Medicare Part D, but not for commercial insurance, Eli Lilly and Company announced on 1 March it will bear the cost of a $35 cap on copays for its insulins in the private market and for the uninsured, effective immediately.

The initiative is an expansion of Lilly’s existing $35 copay program. It involves allowing 85% of retail pharmacies to automatically “buy down” patient cost sharing at the point of sale using technology supplied by the company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.